WO2014162515A1 - Peritoneal dialysis fluid - Google Patents

Peritoneal dialysis fluid Download PDF

Info

Publication number
WO2014162515A1
WO2014162515A1 PCT/JP2013/060075 JP2013060075W WO2014162515A1 WO 2014162515 A1 WO2014162515 A1 WO 2014162515A1 JP 2013060075 W JP2013060075 W JP 2013060075W WO 2014162515 A1 WO2014162515 A1 WO 2014162515A1
Authority
WO
WIPO (PCT)
Prior art keywords
peritoneal dialysis
liquid
solution
icodextrin
dialysis solution
Prior art date
Application number
PCT/JP2013/060075
Other languages
French (fr)
Japanese (ja)
Inventor
義彦 小山
浩一 宇佐美
西谷　弘
剛 有泉
Original Assignee
テルモ株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by テルモ株式会社 filed Critical テルモ株式会社
Priority to PCT/JP2013/060075 priority Critical patent/WO2014162515A1/en
Priority to JP2015509768A priority patent/JP6216777B2/en
Publication of WO2014162515A1 publication Critical patent/WO2014162515A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
    • A61M1/1654—Dialysates therefor
    • A61M1/1656—Apparatus for preparing dialysates
    • A61M1/1668—Details of containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
    • A61M1/287—Dialysates therefor

Definitions

  • the present invention relates to a peritoneal dialysis solution containing icodextrin.
  • Peritoneal dialysis which is one of the symptomatic treatments for renal failure, is one of the home medical treatments because it requires less equipment and instruments and less time constraints than dialysis performed by artificial kidneys.
  • Many peritoneal dialysates currently in use use glucose as an osmotic substance.
  • Glucose has the advantage of being relatively safe and inexpensive, but because of its low molecular weight, it is rapidly absorbed from the peritoneum and cannot provide a continuous water removal effect. From the above situation, a search for an osmotic substance instead of glucose capable of maintaining ultrafiltration during long-time storage has been conducted, and it has been found that icodextrin, a glucose polymer, is suitable for peritoneal dialysis fluid.
  • Icodextrin has a large molecular weight, so it is not absorbed rapidly through the peritoneum, but acts mainly as a colloid osmotic substance, and can obtain a water removal effect while maintaining the osmotic pressure with plasma. .
  • peritoneal dialysis fluids that use icodextrin are formulated so that the drug solution is in the range of pH 5.0 to 5.5 in order to prevent decomposition and coloring of icodextrin.
  • the pH of the peritoneal dialysis fluid has a great influence on the stability of icodextrin. If the pH is increased as it is, the icodextrin is decomposed into glucose during production and storage, and the peritoneal dialysis fluid is degraded due to the deterioration of the glucose. Coloring will result in a significant reduction in product value. That is, the absorbance at 284 nm, which is an indicator of 5-hydroxymethylfurfural, which is the main degradation product of glucose, increases over time.
  • Patent Document 1 A formulation has been developed (Patent Document 1).
  • Patent Document 1 JP 2010-150281
  • the present invention provides a peritoneal dialysis solution that maximizes the stability of icodextrin during heat sterilization and subsequent storage, and has a pH close to a physiological range.
  • the present invention provides a sterilized peritoneal dialysis solution comprising an acidic first liquid containing 300.0 to 500.0 g / L icodextrin and an alkaline second liquid containing an alkaline pH adjuster.
  • the pH of the first liquid after sterilization is 4.5 to 5.5
  • the pH of the second liquid after sterilization is 6.5 to 7.5
  • the first liquid and the second liquid are sterilized after sterilization.
  • This is a peritoneal dialysis solution having a pH of 6.0 to 7.5 after mixing.
  • the present invention is the peritoneal dialysis solution according to the above (1), wherein the first solution contains neither lactic acid nor lactate.
  • the lactate include sodium lactate, potassium lactate, and calcium lactate.
  • the present invention is the peritoneal dialysis solution according to the above (1), wherein the alkaline pH adjuster of the second solution contains at least one of sodium hydroxide and sodium bicarbonate.
  • the present invention is the peritoneal dialysis solution according to (1), wherein the second solution contains at least one of sodium chloride, lactic acid, sodium lactate, calcium chloride, and magnesium chloride.
  • the present invention is the peritoneal dialysis solution described in (1) above, which is housed in a medical bag body, and the bag body is formed by being separated by a partitioning means capable of opening the inside thereof.
  • a first chamber and a second chamber, and the second chamber has a discharge port communicating between the inside and the outside of the bag body, and the first liquid is in the first chamber, and the second liquid is in the second chamber.
  • the peritoneal dialysis fluid of the present invention is obtained by separating peritoneal dialysis fluid over time with a peritoneal dialysis fluid that separates and stores components of peritoneal dialysis fluid containing icodextrin and alkaline peritoneal dialysis fluid, particularly lactic acid and lactate.
  • the increase in absorbance at 284 nm can be suppressed, that is, the glucose degradation product of icodextrin during heat sterilization and subsequent storage can be significantly suppressed, and a peritoneal dialysis solution having excellent stability can be provided.
  • the peritoneal dialysis solution of the present invention is composed of a first liquid mainly containing icodextrin and a second liquid containing no icodextrin and containing an alkaline pH adjuster, and the first liquid and the second liquid are mixed immediately before use.
  • This is a two-part peritoneal dialysis solution, which has a pH of 6.0 to 7.5 after mixing.
  • the content of icodextrin in the first liquid is 300.0 to 500.0 g / L, preferably 350.0 to 400.0 g / L.
  • the content of icodextrin is less than 300.0 g / L, the osmotic pressure after mixing the first liquid and the second liquid is too low to expect sufficient dialysis, and the icodextrin contained in the first liquid
  • the content of dextrin exceeds 500.0 g / L, the content of glucose degradation products increases, which is not preferable. That is, as a result, the decomposition of icodextrin into glucose during heat sterilization and subsequent storage can be suitably suppressed, and a peritoneal dialysis solution that is stable and excellent in storage stability can be realized.
  • the pH of the first liquid after sterilization is in the acidic region, specifically, the range of pH 4.5 to 5.5 is preferable, and the range of pH 4.7 to 5.3 is more preferable. If the pH is less than 4.5 or more than 5.5, the amount of glucose degradation product increases, which is not preferable.
  • the pH may be adjusted using, for example, hydrochloric acid or lactic acid.
  • the second liquid contains at least one of sodium hydroxide and sodium hydrogen carbonate as an alkaline pH adjuster.
  • the content of the alkaline pH adjuster is such that at least one of lactate or lactic acid blended as an alkalinizing agent is added, and the sterilized first and second liquids are mixed to adjust the pH of the retroperitoneal dialysis solution to pH 6.0. -7.5, preferably the amount necessary to adjust the pH to 6.5-7.5.
  • the pH after mixing is less than 6.0, the immune defense mechanism of macrophages is reduced and the peritoneal mesothelial cells are highly impaired. Concerned.
  • At least one of lactate or lactic acid blended as an alkalizing agent is contained, and the content thereof is not particularly limited, as long as the lactate ion contains the same amount as a normal peritoneal dialysis solution. It is preferably 30 to 45 mEq / L as a lactate ion after mixing.
  • the alkalinizing agent may be contained in either the first liquid or the second liquid.
  • icodextrin is decomposed into glucose, and icodextrin is used in terms of stability of the peritoneal dialysis solution, such as inhibition of glucose degradation. It is preferable to mix in the second liquid not contained.
  • the lactate include sodium lactate, potassium lactate, and calcium lactate, and preferably sodium lactate.
  • the peritoneal dialysis solution of the present invention contains various components contained in a normal peritoneal dialysis solution, that is, sodium ions, calcium ions, magnesium ions, chlorine ions, and the like. These contents may be the same as the normal peritoneal dialysis solution.
  • sodium ions are 100 to 200 mEq / L
  • calcium ions are 0 to 5 mEq / L
  • magnesium ions are It is preferably 0 to 5 mEq / L and the chlorine ion is preferably 50 to 180 mEq / L.
  • These components may be contained in either the first liquid or the second liquid, but are preferably blended into the second liquid not containing icodextrin from the viewpoint of the stability of the peritoneal dialysis liquid.
  • These components may be blended in the peritoneal dialysis solution of the present invention as lactic acid, sodium lactate, sodium chloride, calcium chloride, magnesium chloride, etc. in the same manner as a normal peritoneal dialysis solution.
  • the first solution and the second solution are separately filled and packaged in a container made of polypropylene or polyvinyl chloride, sterilized, and immediately before use, the first solution and the second solution The solution is mixed aseptically.
  • the peritoneal dialysis solution of the present invention is a medical bag body, which has a first chamber and a second chamber formed by being separated by a partitioning means capable of opening the inside thereof. It is preferable that the first liquid and the second liquid are separated and accommodated in one having a discharge port that communicates the inside and outside of the medical bag body. At this time, it is preferable to store the first liquid in the first chamber and the second liquid in the second chamber. Thus, even if the first liquid and the second liquid are administered without mixing, administration of the second liquid that is relatively safe in terms of osmotic pressure can be administered.
  • the partitioning means that can be opened, there is a heat seal that can be broken by the hydraulic pressure of the first liquid or the second liquid stored when one of the first chamber or the second chamber is pressed. Thereby, mixing with a 1st liquid and a 2nd liquid can be performed easily.
  • a medical bag specifically, a container of Midperic (registered trademark) (manufactured by Terumo Corporation) can be mentioned.
  • the sterilization method includes autoclave sterilization (high pressure steam sterilization), and the condition is preferably 110 to 140 ° C. for 5 to 40 minutes, and specifically 121 ° C. for 10 minutes.
  • Example 1 75 g of icodextrin was dissolved in 200 mL of water for injection to prepare a first solution. Also, 5.35 g of sodium chloride, 4.48 g of sodium lactate, 0.257 g of calcium chloride dihydrate and 0.051 g of magnesium chloride hexahydrate were dissolved in 800 mL of water for injection to obtain sodium hydroxide. The pH was adjusted with a to prepare a second solution.
  • Example 2 75 g of icodextrin was dissolved in 160 mL of water for injection to prepare a first solution. Also, 5.35 g of sodium chloride, 4.48 g of sodium lactate, 0.257 g of calcium chloride dihydrate, and 0.051 g of magnesium chloride hexahydrate were dissolved in 840 mL of water for injection to obtain sodium hydroxide. The pH was adjusted with a to prepare a second solution. After filling and heat-sterilizing 160 mL of the first solution and 840 mL of the second solution under the same conditions as in Example 1, the pH of the first solution, the second solution, and the mixed solution (peritoneal dialysis solution) was measured. The pH of the first solution was 4.7, the pH of the second solution was 7.0, and the pH of the mixed solution was 6.6.
  • the peritoneal dialysis solution of the present invention can be peritoneal dialysis of less than 0.15 at an absorbance of 284 nm after heat sterilization or after lapse of 7 days at 60 ° C. by performing appropriate heat sterilization. Liquid can be realized. This is something that could not have been predicted from the prior art.
  • the peritoneal dialysis solution of the present invention can adjust the pH to a physiological range, suppress the decomposition of icodextrin during heat sterilization and subsequent storage to the maximum, and is extremely stable. It can be used industrially as an excellent peritoneal dialysis solution.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • External Artificial Organs (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention is a sterile peritoneal dialysis fluid comprising an acidic first fluid containing 300.0 to 500.0 g/L of icodextrin and an alkaline second fluid containing an alkaline pH regulator, wherein the pH of the sterilized first fluid is 4.5 to 5.0, the pH of the sterilized second fluid is 6.5 to 7.5, and the pH after mixing the sterilized first and the second fluids is 6.0 to 7.5. The present invention provides a peritoneal dialysis fluid containing icodextrin, wherein the stability of the icodextrin during heat sterilization and subsequent storage can be improved to the utmost and the peritoneal dialysis fluid has a pH near the physiological range.

Description

腹膜透析液Peritoneal dialysate
　本発明は、イコデキストリンを含有する腹膜透析液に関する。 The present invention relates to a peritoneal dialysis solution containing icodextrin.
　腎不全の対症療法の１つである腹膜透析療法は、人工腎臓によって行われる透析療法に比して装置や器具が大がかりとならず、時間的な拘束も少ないことから在宅医療の一つとして注目されている。現在使用されている多くの腹膜透析液は、浸透圧物質としてブドウ糖を使用している。ブドウ糖は、比較的安全で、安価であるという利点を有するが、分子量が小さいため、腹膜から急速に吸収され、持続的な除水効果が得られない。以上の状況から、長時間貯留時において限外濾過を維持できるブドウ糖に代わる浸透圧物質の探索が行われ、ブドウ糖ポリマーであるイコデキストリンが腹膜透析液に適することが見出されている。 Peritoneal dialysis, which is one of the symptomatic treatments for renal failure, is one of the home medical treatments because it requires less equipment and instruments and less time constraints than dialysis performed by artificial kidneys. Has been. Many peritoneal dialysates currently in use use glucose as an osmotic substance. Glucose has the advantage of being relatively safe and inexpensive, but because of its low molecular weight, it is rapidly absorbed from the peritoneum and cannot provide a continuous water removal effect. From the above situation, a search for an osmotic substance instead of glucose capable of maintaining ultrafiltration during long-time storage has been conducted, and it has been found that icodextrin, a glucose polymer, is suitable for peritoneal dialysis fluid.
　イコデキストリンは、分子量が大きいため、腹膜を介して急速に吸収されることもなく、主として膠質浸透圧物質として作用し、血漿との浸透圧を維持しながら除水効果を得ることが可能である。現在、イコデキストリンを使用している腹膜透析液は、イコデキストリンの分解・着色を防止するため、薬液がｐＨ５．０～５．５の範囲になるように処方される。 Icodextrin has a large molecular weight, so it is not absorbed rapidly through the peritoneum, but acts mainly as a colloid osmotic substance, and can obtain a water removal effect while maintaining the osmotic pressure with plasma. . Currently, peritoneal dialysis fluids that use icodextrin are formulated so that the drug solution is in the range of pH 5.0 to 5.5 in order to prevent decomposition and coloring of icodextrin.
　最近の研究によると、このようなｐＨの腹膜透析液は、腹腔マクロファージの免疫防御機構を実質的に低下させてしまい、細菌の進入に対して腹膜炎の危険性を増大させることが報告されている。さらに、ｐＨが５．０～５．５の腹膜透析液は、培養腹膜中皮細胞への障害性が著しく高く、障害性を軽減するためには、腹膜透析液のｐＨを６．５以上にすることが有効であることが報告されている。 Recent studies have reported that such pH peritoneal dialysis solutions substantially reduce the immune defense mechanism of peritoneal macrophages and increase the risk of peritonitis against bacterial invasion. . Furthermore, the peritoneal dialysis solution having a pH of 5.0 to 5.5 has extremely high damage to cultured peritoneal mesothelial cells. To reduce the damage, the pH of the peritoneal dialysis solution is increased to 6.5 or more. It has been reported to be effective.
　しかしながら、腹膜透析液のｐＨは、イコデキストリンの安定性に大きな影響を与えており、そのままｐＨを高くすると、製造時や保管時にイコデキストリンがブドウ糖に分解し、そのブドウ糖の劣化により腹膜透析液が着色してしまい、製品価値が著しく低下してしまうことになる。すなわち、ブドウ糖の主たる分解生成物である５－ヒドロキシメチルフルフラールの指標である２８４ｎｍの吸光度が、継時的に増加してしまう。 However, the pH of the peritoneal dialysis fluid has a great influence on the stability of icodextrin. If the pH is increased as it is, the icodextrin is decomposed into glucose during production and storage, and the peritoneal dialysis fluid is degraded due to the deterioration of the glucose. Coloring will result in a significant reduction in product value. That is, the absorbance at 284 nm, which is an indicator of 5-hydroxymethylfurfural, which is the main degradation product of glucose, increases over time.
　そこで、イコデキストリンの分解・着色を抑制したまま、腹膜透析液のｐＨを高くする方法として、イコデキストリンと、ｐＨの高い薬液成分とを使用時まで別々に収容し、使用直前に無菌的に混合する製剤が開発されている（特許文献１）。 Therefore, as a method of increasing the pH of the peritoneal dialysis solution while suppressing decomposition and coloring of icodextrin, icodextrin and a high-pH chemical component are separately stored until use and mixed aseptically immediately before use. A formulation has been developed (Patent Document 1).
　しかしながら、腹膜透析液の安定性や、腹膜透析液の安全性に対する要求は、近年、ますます高次元になっており、人体に悪影響を与えない生理的なｐＨで、かつ、イコデキストリンのブドウ糖への分解や着色を好適に抑制した、安定な腹膜透析液の出現が望まれている。 However, the demand for the stability of peritoneal dialysis fluid and the safety of peritoneal dialysis fluid has become increasingly high in recent years, at a physiological pH that does not adversely affect the human body, and to the glucose of icodextrin. The appearance of a stable peritoneal dialysis solution that suitably suppresses the decomposition and coloring of is desired.
特許文献１：特開２０１０－１５０２８１ Patent Document 1: JP 2010-150281
　本発明は、加熱滅菌およびその後の保管中のイコデキストリンの安定性を最大限に向上し、かつ、ｐＨが生理的な領域に近い腹膜透析液を提供することにある。 The present invention provides a peritoneal dialysis solution that maximizes the stability of icodextrin during heat sterilization and subsequent storage, and has a pH close to a physiological range.
　上記の課題は、以下の本発明により達成される。 The above-mentioned problems are achieved by the following present invention.
　（１）本発明は、３００．０～５００．０ｇ／Ｌのイコデキストリンを含有する酸性の第１液と、アルカリ性ｐＨ調整剤を含有するアルカリ性の第２液とからなる滅菌された腹膜透析液であって、滅菌後の前記第１液のｐＨが４．５～５．５、滅菌後の前記第２液のｐＨが６．５～７．５、滅菌後に第１液と第２液を混合した後のｐＨが６．０～７．５となる腹膜透析液である。 (1) The present invention provides a sterilized peritoneal dialysis solution comprising an acidic first liquid containing 300.0 to 500.0 g / L icodextrin and an alkaline second liquid containing an alkaline pH adjuster. The pH of the first liquid after sterilization is 4.5 to 5.5, the pH of the second liquid after sterilization is 6.5 to 7.5, and the first liquid and the second liquid are sterilized after sterilization. This is a peritoneal dialysis solution having a pH of 6.0 to 7.5 after mixing.
　（２）本発明は、前記第１液には、乳酸および乳酸塩のいずれも含まない上記（１）に記載の腹膜透析液である。ここで、乳酸塩としては、乳酸ナトリウム、乳酸カリウム、乳酸カルシウムなどがあげられる。 (2) The present invention is the peritoneal dialysis solution according to the above (1), wherein the first solution contains neither lactic acid nor lactate. Here, examples of the lactate include sodium lactate, potassium lactate, and calcium lactate.
　（３）本発明は、前記第２液のアルカリ性ｐＨ調整剤が、水酸化ナトリウムおよび炭酸水素ナトリウムの少なくとも一つを含む上記（１）に記載の腹膜透析液である。 (3) The present invention is the peritoneal dialysis solution according to the above (1), wherein the alkaline pH adjuster of the second solution contains at least one of sodium hydroxide and sodium bicarbonate.
　（４）本発明は、前記第２液が、塩化ナトリウム、乳酸、乳酸ナトリウム、塩化カルシウム、および塩化マグネシウムの少なくとも一つを含む上記（１）に記載の腹膜透析液である。 (4) The present invention is the peritoneal dialysis solution according to (1), wherein the second solution contains at least one of sodium chloride, lactic acid, sodium lactate, calcium chloride, and magnesium chloride.
　（５）本発明は、医療用袋体に収納された上記（１）に記載の腹膜透析液であって、前記袋体は、その内部を開放可能な仕切手段によって分離されることにより形成される第１室と第２室とを有し、前記第２室は前記袋体の内外を連通する排出ポートを有するものであって、前記第１液は前記第１室に、前記第２液は前記第２室に収納されている腹膜透析液である。 (5) The present invention is the peritoneal dialysis solution described in (1) above, which is housed in a medical bag body, and the bag body is formed by being separated by a partitioning means capable of opening the inside thereof. A first chamber and a second chamber, and the second chamber has a discharge port communicating between the inside and the outside of the bag body, and the first liquid is in the first chamber, and the second liquid is in the second chamber. Is a peritoneal dialysis solution stored in the second chamber.
　本発明の腹膜透析液は、イコデキストリンを含む腹膜透析液の成分と、アルカリ性の腹膜透析液の成分、特に乳酸および乳酸塩とを分離して保管する腹膜透析液により、腹膜透析液の経時的な２８４ｎｍの吸光度の増加を抑制できること、すなわち、加熱滅菌およびその後の保管中のイコデキストリンのブドウ糖分解物を大幅に抑制し、安定性に優れた腹膜透析液を提供することができる。 The peritoneal dialysis fluid of the present invention is obtained by separating peritoneal dialysis fluid over time with a peritoneal dialysis fluid that separates and stores components of peritoneal dialysis fluid containing icodextrin and alkaline peritoneal dialysis fluid, particularly lactic acid and lactate. The increase in absorbance at 284 nm can be suppressed, that is, the glucose degradation product of icodextrin during heat sterilization and subsequent storage can be significantly suppressed, and a peritoneal dialysis solution having excellent stability can be provided.
　以下、本発明の腹膜透析液について、詳細に説明する。本発明の腹膜透析液は、主としてイコデキストリンを含有する第１液と、イコデキストリンを含まずアルカリ性ｐＨ調整剤を含む第２液とからなり、使用直前に第１液および第２液を混合する２液型の腹膜透析液で、混合後のｐＨが６．０～７．５の腹膜透析液である。 Hereinafter, the peritoneal dialysis solution of the present invention will be described in detail. The peritoneal dialysis solution of the present invention is composed of a first liquid mainly containing icodextrin and a second liquid containing no icodextrin and containing an alkaline pH adjuster, and the first liquid and the second liquid are mixed immediately before use. This is a two-part peritoneal dialysis solution, which has a pH of 6.0 to 7.5 after mixing.
　本発明において、第１液のイコデキストリンの含有量は、３００．０～５００．０ｇ／Ｌ、好ましくは、３５０．０～４００．０ｇ／Ｌである。イコデキストリンの含有量が３００．０ｇ／Ｌ未満の場合、第１液と第２液を混合した後の浸透圧が低すぎて十分な透析が期待できず、また、第１液に含まれるイコデキストリンの含有量が５００．０ｇ／Ｌを超える場合、ブドウ糖分解物の含有量が多くなり好ましくない。すなわち、これにより、加熱滅菌およびその後の保管中のイコデキストリンのブドウ糖への分解を好適に抑制することができ、安定で保存性に優れる腹膜透析液が実現できる。 In the present invention, the content of icodextrin in the first liquid is 300.0 to 500.0 g / L, preferably 350.0 to 400.0 g / L. When the content of icodextrin is less than 300.0 g / L, the osmotic pressure after mixing the first liquid and the second liquid is too low to expect sufficient dialysis, and the icodextrin contained in the first liquid When the content of dextrin exceeds 500.0 g / L, the content of glucose degradation products increases, which is not preferable. That is, as a result, the decomposition of icodextrin into glucose during heat sterilization and subsequent storage can be suitably suppressed, and a peritoneal dialysis solution that is stable and excellent in storage stability can be realized.
　滅菌後の第１液のｐＨは、酸性領域であり、具体的には、ｐＨ４．５～５．５の範囲が好ましく、ｐＨ４．７～５．３の範囲がより好ましい。ｐＨが４．５未満あるいはｐＨ５．５を超えると、グルコース分解物の量が多くなるため好ましくない。 The pH of the first liquid after sterilization is in the acidic region, specifically, the range of pH 4.5 to 5.5 is preferable, and the range of pH 4.7 to 5.3 is more preferable. If the pH is less than 4.5 or more than 5.5, the amount of glucose degradation product increases, which is not preferable.
　また、必要があれば、例えば、塩酸や乳酸等を用いてｐＨ調整を行ってもよい。 If necessary, the pH may be adjusted using, for example, hydrochloric acid or lactic acid.
　また、本発明において、第２液は、アルカリ性ｐＨ調整剤として、水酸化ナトリウムおよび炭酸水素ナトリウムの少なくとも一つを含むものである。アルカリ性ｐＨ調整剤の含有量は、アルカリ化剤として配合される乳酸塩または乳酸の少なくとも一つを加え、滅菌後の第１液及び第２液を混合した後腹膜透析液のｐＨをｐＨ６．０～７．５、好ましくは、ｐＨ６．５～７．５に調整するために必要な量である。 In the present invention, the second liquid contains at least one of sodium hydroxide and sodium hydrogen carbonate as an alkaline pH adjuster. The content of the alkaline pH adjuster is such that at least one of lactate or lactic acid blended as an alkalinizing agent is added, and the sterilized first and second liquids are mixed to adjust the pH of the retroperitoneal dialysis solution to pH 6.0. -7.5, preferably the amount necessary to adjust the pH to 6.5-7.5.
　本発明の腹膜透析液において、混合後のｐＨが６．０未満では、マクロファージの免疫防御機構の低下や、腹膜中皮細胞への障害性が高く、７．５を超えると、生体に対する悪影響が懸念される。 In the peritoneal dialysis solution of the present invention, if the pH after mixing is less than 6.0, the immune defense mechanism of macrophages is reduced and the peritoneal mesothelial cells are highly impaired. Concerned.
　本発明において、アルカリ化剤として配合される乳酸塩または乳酸の少なくとも一つが含有され、その含有量は、特に限定はなく、乳酸イオンとして通常の腹膜透析液と同様の量が含まれていればよく、好ましくは、混合後において、乳酸イオンとして、３０～４５ｍＥｑ／Ｌである。アルカリ化剤は、第１液および第２液のいずれに含有されてもよいが、イコデキストリンがブドウ糖に分解し、そのブドウ糖の分解抑制等の腹膜透析液の安定性の点で、イコデキストリンを含有しない第２液に配合するのが好ましい。乳酸塩としては、乳酸ナトリウム、乳酸カリウム、乳酸カルシウムなどがあげられ、好ましくは乳酸ナトリウムがあげられる。 In the present invention, at least one of lactate or lactic acid blended as an alkalizing agent is contained, and the content thereof is not particularly limited, as long as the lactate ion contains the same amount as a normal peritoneal dialysis solution. It is preferably 30 to 45 mEq / L as a lactate ion after mixing. The alkalinizing agent may be contained in either the first liquid or the second liquid. However, icodextrin is decomposed into glucose, and icodextrin is used in terms of stability of the peritoneal dialysis solution, such as inhibition of glucose degradation. It is preferable to mix in the second liquid not contained. Examples of the lactate include sodium lactate, potassium lactate, and calcium lactate, and preferably sodium lactate.
　本発明の腹膜透析液には、これらの成分以外にも、通常の腹膜透析液に含有される各種の成分、すなわちナトリウムイオン、カルシウムイオン、マグネシウムイオン、塩素イオン等が含有される。これらの含有量は、通常の腹膜透析液と同様でよく、第１液と第２液との混合後において、ナトリウムイオンは１００～２００ｍＥｑ／Ｌ、カルシウムイオンは０～５ｍＥｑ／Ｌ、マグネシウムイオンは０～５ｍＥｑ／Ｌ、塩素イオンは５０ ～１８０ｍＥｑ／Ｌであることが、それぞれ好ましい。 In addition to these components, the peritoneal dialysis solution of the present invention contains various components contained in a normal peritoneal dialysis solution, that is, sodium ions, calcium ions, magnesium ions, chlorine ions, and the like. These contents may be the same as the normal peritoneal dialysis solution. After mixing the first and second fluids, sodium ions are 100 to 200 mEq / L, calcium ions are 0 to 5 mEq / L, and magnesium ions are It is preferably 0 to 5 mEq / L and the chlorine ion is preferably 50 to 180 mEq / L.
　これらの成分は、第１液および第２液のいずれに含有されてもよいが、腹膜透析液の安定性の点で、イコデキストリンを含有しない第２液に配合するのが好ましい。また、これらの成分は、通常の腹膜透析液と同様に、乳酸、乳酸ナトリウム、塩化ナトリウム、塩化カルシウム、塩化マグネシウム等として、本発明の腹膜透析液に配合すればよい。 These components may be contained in either the first liquid or the second liquid, but are preferably blended into the second liquid not containing icodextrin from the viewpoint of the stability of the peritoneal dialysis liquid. These components may be blended in the peritoneal dialysis solution of the present invention as lactic acid, sodium lactate, sodium chloride, calcium chloride, magnesium chloride, etc. in the same manner as a normal peritoneal dialysis solution.
　本発明の腹膜透析液は、第１液と第２液とが、別々に、ポリプロピレン製やポリ塩化ビニル製等の容器に充填・包装され、滅菌され、使用直前に、第１液と第２液とが無菌的に混合される。 In the peritoneal dialysis solution of the present invention, the first solution and the second solution are separately filled and packaged in a container made of polypropylene or polyvinyl chloride, sterilized, and immediately before use, the first solution and the second solution The solution is mixed aseptically.
　特に、本発明の腹膜透析液は、医療用袋体であって、その内部を開放可能な仕切手段によって分離されることにより形成される第１室と第２室とを有し、第２室には医療用袋体の内外を連通する排出ポートを有するものに、第１液と第２液とを分離して収納されることが好ましい。このとき、第１液は第１室に、第２液は第２室に収納することが好ましい。これによって、万が一、第１液と第２液とを混合せずに投与してしまった場合にも、浸透圧的に比較的安全な第２液の投与を投与することができる。 In particular, the peritoneal dialysis solution of the present invention is a medical bag body, which has a first chamber and a second chamber formed by being separated by a partitioning means capable of opening the inside thereof. It is preferable that the first liquid and the second liquid are separated and accommodated in one having a discharge port that communicates the inside and outside of the medical bag body. At this time, it is preferable to store the first liquid in the first chamber and the second liquid in the second chamber. Thus, even if the first liquid and the second liquid are administered without mixing, administration of the second liquid that is relatively safe in terms of osmotic pressure can be administered.
　開放可能な仕切手段としては、第１室または第２室の一方を押圧した際に、その収納されている第１液または第２液の液圧で破断できるヒート・シールが挙げられる。これにより、第１液と第２液との混合を容易に行うことができる。医療用袋体としては、具体的には、ミッドペリック（登録商標）（テルモ株式会社製）の容器があげられる。 As the partitioning means that can be opened, there is a heat seal that can be broken by the hydraulic pressure of the first liquid or the second liquid stored when one of the first chamber or the second chamber is pressed. Thereby, mixing with a 1st liquid and a 2nd liquid can be performed easily. As a medical bag, specifically, a container of Midperic (registered trademark) (manufactured by Terumo Corporation) can be mentioned.
　本発明において、滅菌方法としては、オートクレーブ滅菌（高圧蒸気滅菌）が挙げられ、その条件としては、１１０～１４０℃で５～４０分間が好ましく、具体的には１２１℃で１０分間である。 In the present invention, the sterilization method includes autoclave sterilization (high pressure steam sterilization), and the condition is preferably 110 to 140 ° C. for 5 to 40 minutes, and specifically 121 ° C. for 10 minutes.
　以上、本発明の腹膜透析液について詳細に説明したが、本発明は、これに限定はされず、本発明の要旨を逸脱しない範囲において、各種の改良および変更を行ってもよい。 Although the peritoneal dialysis solution of the present invention has been described in detail above, the present invention is not limited to this, and various improvements and modifications may be made without departing from the scope of the present invention.
　以下、本発明の具体的実施例を挙げ、本発明をより詳細に説明する。なお、本発明は、以下の実施例に限定されるものではない。 Hereinafter, the present invention will be described in more detail with reference to specific examples of the present invention. The present invention is not limited to the following examples.
　（実施例１）
　７５ｇのイコデキストリンを２００ｍＬの注射用水に溶解し、第１液を調製した。また、５．３５ｇの塩化ナトリウム、４．４８ｇの乳酸ナトリウム、０．２５７ｇの塩化カルシウム・二水塩、および０．０５１ｇの塩化マグネシウム・六水塩を８００ｍＬの注射用水に溶解し、水酸化ナトリウムでｐＨを調整し、第２液を調製した。第１液２００ｍＬ、第２液８００ｍＬを、それぞれポリプロピレン製複室容器（ミッドペリック（登録商標）（テルモ株式会社製）の容器）に充填した後、ポリプロピレン／ナイロン／ポリプロピレン製の三方袋に入れて脱気包装した。その後、オートクレーブを用いて加熱滅菌（１２１℃、１０分）を行った後、第１液、第２液、および混合液（腹膜透析液）のｐＨを測定した。第１液のｐＨは４．８、第２液のｐＨは６．９、混合液のｐＨは６．７であった。 (Example 1)
75 g of icodextrin was dissolved in 200 mL of water for injection to prepare a first solution. Also, 5.35 g of sodium chloride, 4.48 g of sodium lactate, 0.257 g of calcium chloride dihydrate and 0.051 g of magnesium chloride hexahydrate were dissolved in 800 mL of water for injection to obtain sodium hydroxide. The pH was adjusted with a to prepare a second solution. After filling 200 mL of the first liquid and 800 mL of the second liquid into a polypropylene multi-chamber container (a container of Midperic (registered trademark) (manufactured by Terumo Corporation)), it is put in a three-sided bag made of polypropylene / nylon / polypropylene and removed. I wrapped it. Then, after performing heat sterilization (121 degreeC, 10 minutes) using an autoclave, pH of the 1st liquid, the 2nd liquid, and a liquid mixture (peritoneal dialysate) was measured. The pH of the first solution was 4.8, the pH of the second solution was 6.9, and the pH of the mixed solution was 6.7.
　（実施例２）
　７５ｇのイコデキストリンを１６０ｍＬの注射用水に溶解し、第１液を調製した。また、５．３５ｇの塩化ナトリウム、４．４８ｇの乳酸ナトリウム、０．２５７ｇの塩化カルシウム・二水塩、および０．０５１ｇの塩化マグネシウム・六水塩を８４０ｍＬの注射用水に溶解し、水酸化ナトリウムでｐＨを調整し、第２液を調製した。第１液１６０ｍＬ、第２液８４０ｍＬを、実施例１と同様の条件で、充填、加熱滅菌した後、第１液、第２液、および混合液（腹膜透析液）のｐＨを測定した。第１液のｐＨは４．７、第２液のｐＨは７．０、混合液のｐＨは６．６であった。 (Example 2)
75 g of icodextrin was dissolved in 160 mL of water for injection to prepare a first solution. Also, 5.35 g of sodium chloride, 4.48 g of sodium lactate, 0.257 g of calcium chloride dihydrate, and 0.051 g of magnesium chloride hexahydrate were dissolved in 840 mL of water for injection to obtain sodium hydroxide. The pH was adjusted with a to prepare a second solution. After filling and heat-sterilizing 160 mL of the first solution and 840 mL of the second solution under the same conditions as in Example 1, the pH of the first solution, the second solution, and the mixed solution (peritoneal dialysis solution) was measured. The pH of the first solution was 4.7, the pH of the second solution was 7.0, and the pH of the mixed solution was 6.6.
　（比較例１）
　７５ｇのイコデキストリン、０．２５７ｇの塩化カルシウム・二水塩、および０．０５１ｇの塩化マグネシウム・六水塩を２００ｍＬの注射用水に溶解し、第１液を調製した。また、５．３５ｇの塩化ナトリウムおよび４．４８ｇの乳酸ナトリウムを８００ｍＬの注射用水に溶解し、水酸化ナトリウムでｐＨを調整し、第２液を調製した。第１液２００ｍＬ、第２液８００ｍＬを、実施例１と同様の条件で、充填、加熱滅菌した後、第１液、第２液、および混合液（腹膜透析液）のｐＨを測定した。第１液のｐＨは５．０、第２液のｐＨは６．８、混合液のｐＨは６．６であった。 (Comparative Example 1)
First solution was prepared by dissolving 75 g of icodextrin, 0.257 g of calcium chloride dihydrate and 0.051 g of magnesium chloride hexahydrate in 200 mL of water for injection. In addition, 5.35 g of sodium chloride and 4.48 g of sodium lactate were dissolved in 800 mL of water for injection, and the pH was adjusted with sodium hydroxide to prepare a second solution. After filling and heat-sterilizing 200 mL of the first solution and 800 mL of the second solution under the same conditions as in Example 1, the pH of the first solution, the second solution, and the mixed solution (peritoneal dialysis solution) was measured. The pH of the first solution was 5.0, the pH of the second solution was 6.8, and the pH of the mixed solution was 6.6.
　（比較例２）
　５０ｇのイコデキストリン、０．２５７ｇの塩化カルシウム・二水塩、０．０５１ｇの塩化マグネシウム・六水塩、および５．３５ｇの塩化ナトリウムを２００ｍＬの注射用水に溶解し、第１液を調製した。また、４．４８ｇの乳酸ナトリウムを８００ｍＬの注射用水に溶解し、水酸化ナトリウムでｐＨを調整し、第２液を調製した。第１液２００ｍＬ、第２液８００ｍＬを、実施例１と同様の条件で、充填、加熱滅菌した後、第１液、第２液、および混合液（腹膜透析液）のｐＨを測定した。第１液のｐＨは４．９、第２液のｐＨは６．８、混合液のｐＨは６．６であった。 (Comparative Example 2)
50 g of icodextrin, 0.257 g of calcium chloride dihydrate, 0.051 g of magnesium chloride hexahydrate and 5.35 g of sodium chloride were dissolved in 200 mL of water for injection to prepare a first solution. Further, 4.48 g of sodium lactate was dissolved in 800 mL of water for injection, and the pH was adjusted with sodium hydroxide to prepare a second solution. After filling and heat-sterilizing 200 mL of the first solution and 800 mL of the second solution under the same conditions as in Example 1, the pH of the first solution, the second solution, and the mixed solution (peritoneal dialysis solution) was measured. The pH of the first liquid was 4.9, the pH of the second liquid was 6.8, and the pH of the mixed liquid was 6.6.
　（比較例３）
　７５ｇのイコデキストリン、０．２５７ｇの塩化カルシウム・二水塩、０．０５１ｇの塩化マグネシウム・六水塩、５．３５ｇの塩化ナトリウム、および４．４８ｇの乳酸ナトリウムを注射用水に溶解し、塩酸でｐＨを調整し、１０００ｍＬの溶液を調製した。調製液１０００ｍＬを、ポリプロピレン製単室容器に充填した後、ポリプロピレン／ナイロン／ポリプロピレン製の三方袋に入れて脱気包装した。その後、オートクレーブを用いて加熱滅菌（１２１℃、１０分）を行った後、得られた腹膜透析液のｐＨを測定した。ｐＨは、５．５であった。 (Comparative Example 3)
Dissolve 75 g icodextrin, 0.257 g calcium chloride dihydrate, 0.051 g magnesium chloride hexahydrate, 5.35 g sodium chloride, and 4.48 g sodium lactate in water for injection and use hydrochloric acid. The pH was adjusted and a 1000 mL solution was prepared. 1000 mL of the prepared solution was filled into a single-chamber container made of polypropylene, and then deaerated and packaged in a three-sided bag made of polypropylene / nylon / polypropylene. Thereafter, heat sterilization (121 ° C., 10 minutes) was performed using an autoclave, and then the pH of the obtained peritoneal dialysis solution was measured. The pH was 5.5.
　（経時変化試験）
　実施例１、２、および比較例１～４の腹膜透析液について、ブドウ糖の主たる分解生成物である５－ヒドロキシメチルフルフラールの指標である２８４ｎｍの吸光度の経時的な変化を測定した。結果を表１及び表２に示す。なお、実施例１、２、および比較例１～４の腹膜透析液の保管は６０℃の恒温槽中で行い、第１液と第２液の混合（比較例３は除く）は、吸光度の測定直前に行った。 (Aging test)
With respect to the peritoneal dialysis fluids of Examples 1 and 2 and Comparative Examples 1 to 4, the change over time in the absorbance at 284 nm, which is an index of 5-hydroxymethylfurfural, which is the main degradation product of glucose, was measured. The results are shown in Tables 1 and 2. The peritoneal dialysis fluids of Examples 1 and 2 and Comparative Examples 1 to 4 were stored in a thermostatic bath at 60 ° C., and mixing of the first fluid and the second fluid (except for Comparative Example 3) Performed immediately before the measurement.
Figure JPOXMLDOC01-appb-T000001
Figure JPOXMLDOC01-appb-T000001
Figure JPOXMLDOC01-appb-T000002
Figure JPOXMLDOC01-appb-T000002
　表１及び２に示されるように、本発明の腹膜透析液は、適切な加熱滅菌を行うことによって、加熱滅菌後、あるいは６０℃で７日経過後も２８４ｎｍの吸光度において０．１５未満の腹膜透析液を実現することができる。このことは従来技術からは予測なし得なかったことである。 As shown in Tables 1 and 2, the peritoneal dialysis solution of the present invention can be peritoneal dialysis of less than 0.15 at an absorbance of 284 nm after heat sterilization or after lapse of 7 days at 60 ° C. by performing appropriate heat sterilization. Liquid can be realized. This is something that could not have been predicted from the prior art.
　以上、詳細に説明したように本発明の腹膜透析液は、ｐＨを生理的な領域にできるとともに、加熱滅菌及びその後の保管中のイコデキストリンの分解を最大限に抑制し、非常に安定性に優れた腹膜透析液として産業上利用することができる。 As described above in detail, the peritoneal dialysis solution of the present invention can adjust the pH to a physiological range, suppress the decomposition of icodextrin during heat sterilization and subsequent storage to the maximum, and is extremely stable. It can be used industrially as an excellent peritoneal dialysis solution.

Claims (5)

  1. 　３００．０～５００．０ｇ／Ｌのイコデキストリンを含有する酸性の第１液と、アルカリ性ｐＨ調整剤を含有するアルカリ性の第２液とからなる滅菌された腹膜透析液であって、滅菌後の前記第１液のｐＨが４．５～５．５、滅菌後の前記第２液のｐＨが６．５～７．５、滅菌後に第１液と第２液を混合した後のｐＨが６．０～７．５となる腹膜透析液。 A sterilized peritoneal dialysis solution comprising an acidic first liquid containing 300.0 to 500.0 g / L icodextrin and an alkaline second liquid containing an alkaline pH adjuster, the The pH of the first liquid is 4.5 to 5.5, the pH of the second liquid after sterilization is 6.5 to 7.5, and the pH after mixing the first liquid and the second liquid after sterilization is 6 Peritoneal dialysis solution to be 0 to 7.5.
  2. 　前記第１液には、乳酸および乳酸塩のいずれも含まない請求項１に記載の腹膜透析液。 The peritoneal dialysis solution according to claim 1, wherein the first solution contains neither lactic acid nor lactate.
  3. 　前記第２液のアルカリ性ｐＨ調整剤が、水酸化ナトリウムおよび炭酸水素ナトリウムの少なくとも一つを含む請求項１に記載の腹膜透析液。 The peritoneal dialysis solution according to claim 1, wherein the alkaline pH adjuster of the second solution contains at least one of sodium hydroxide and sodium bicarbonate.
  4. 　前記第２液が、塩化ナトリウム、乳酸、乳酸ナトリウム、塩化カルシウムおよび塩化マグネシウムの少なくとも一つを含む請求項１に記載の腹膜透析液。 The peritoneal dialysis solution according to claim 1, wherein the second solution contains at least one of sodium chloride, lactic acid, sodium lactate, calcium chloride and magnesium chloride.
  5.  　医療用袋体に収納された請求項１に記載の腹膜透析液であって、前記袋体は、その内部を開放可能な仕切手段によって分離されることにより形成される第１室と第２室とを有し、前記第２室は前記袋体の内外を連通する排出ポートを有するものであって、前記第１液は前記第１室に、前記第２液は前記第２室に収納されている腹膜透析液。 The peritoneal dialysis solution according to claim 1, which is housed in a medical bag body, wherein the bag body is formed by being separated by a partitioning means capable of opening the inside thereof. The second chamber has a discharge port that communicates the inside and outside of the bag body, and the first liquid is stored in the first chamber and the second liquid is stored in the second chamber. Peritoneal dialysis fluid.
PCT/JP2013/060075 2013-04-02 2013-04-02 Peritoneal dialysis fluid WO2014162515A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/JP2013/060075 WO2014162515A1 (en) 2013-04-02 2013-04-02 Peritoneal dialysis fluid
JP2015509768A JP6216777B2 (en) 2013-04-02 2013-04-02 Peritoneal dialysate

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2013/060075 WO2014162515A1 (en) 2013-04-02 2013-04-02 Peritoneal dialysis fluid

Publications (1)

Publication Number Publication Date
WO2014162515A1 true WO2014162515A1 (en) 2014-10-09

Family

ID=51657848

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2013/060075 WO2014162515A1 (en) 2013-04-02 2013-04-02 Peritoneal dialysis fluid

Country Status (2)

Country Link
JP (1) JP6216777B2 (en)
WO (1) WO2014162515A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015218141A (en) * 2014-05-19 2015-12-07 テルモ株式会社 Peritoneal dialysate

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08131542A (en) * 1994-11-11 1996-05-28 Baxter Kk Peritoneum dialysing liquid conditioning solution set
JP2006513211A (en) * 2002-12-20 2006-04-20 バクスター インターナショナル インコーポレイテッド Biocompatible dialysate containing icodextrin

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08131542A (en) * 1994-11-11 1996-05-28 Baxter Kk Peritoneum dialysing liquid conditioning solution set
JP2006513211A (en) * 2002-12-20 2006-04-20 バクスター インターナショナル インコーポレイテッド Biocompatible dialysate containing icodextrin

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015218141A (en) * 2014-05-19 2015-12-07 テルモ株式会社 Peritoneal dialysate

Also Published As

Publication number Publication date
JP6216777B2 (en) 2017-10-18
JPWO2014162515A1 (en) 2017-02-16

Similar Documents

Publication Publication Date Title
US11617764B2 (en) Peritoneal dialysis fluid
WO2014083613A1 (en) Peritoneal dialysis fluid
JP6313653B2 (en) Peritoneal dialysate
JP3871442B2 (en) Peritoneal dialysate
JP2010042312A (en) Solution set for preparation of peritoneal dialysis fluid
JP6216777B2 (en) Peritoneal dialysate
JP6944932B2 (en) Biocompatible peritoneal dialysate
JP6419615B2 (en) Peritoneal dialysate
CN105769902A (en) Production process of sodium bicarbonate injection
JP7038106B2 (en) Peritoneal dialysate
JP2008119509A (en) Solution set for preparation of peritoneal dialysis fluid
JP4419904B2 (en) Peritoneal dialysate
JP6958265B2 (en) Replenisher for blood filtration
JP2006223897A (en) Multi-chamber container preparation for storing replenishment fluid
JP2004283619A (en) Solution set for preparation of peritoneal dialysis fluid

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13880862

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2015509768

Country of ref document: JP

Kind code of ref document: A

122 Ep: pct application non-entry in european phase

Ref document number: 13880862

Country of ref document: EP

Kind code of ref document: A1